Post-Traumatic Seizure Prevention and Management in Moderate-to-Severe TBI
Primary Recommendation
Administer levetiracetam for early seizure prophylaxis (≤7 days) in patients with moderate-to-severe TBI (GCS ≤12) or high-risk features, but do not continue prophylaxis beyond 7 days unless clinical seizures occur. 1
High-Risk Features Requiring Prophylaxis
Initiate antiepileptic prophylaxis when any of the following are present:
- Intracranial hemorrhage (including traumatic subarachnoid hemorrhage, subdural hematoma, brain contusion) 2, 1
- Depressed skull fracture 2, 1
- Loss of consciousness or amnesia >24 hours 2, 3
- Age >65 years 2, 3
- Chronic subdural hematoma 2
- Prior history of epilepsy 2
- Craniectomy (emerging risk factor) 2
First-Line Agent: Levetiracetam Dosing
Loading dose: 1000–1500 mg IV as a single bolus 1
Maintenance dose:
- 500–1500 mg IV or PO twice daily 1
- Practical approach: Use 1000 mg twice daily for patients with multiple risk factors or severe injury; 500 mg twice daily for isolated risk factors 1
Duration: Maximum 7 days unless clinical seizures occur 2, 1
Renal adjustment: For hemodialysis patients, give supplemental dose of 250–500 mg after each dialysis session 1
Why Levetiracetam Over Phenytoin
Levetiracetam is strongly preferred because:
- Superior tolerability profile with fewer adverse events on functional outcome scales (Glasgow Outcome Scale-Extended, Disability Rating Scale) 1
- No significant drug interactions 1
- Comparable efficacy to phenytoin for early seizure prevention (OR 0.83,95% CI 0.33-2.1) 4
- Phenytoin is associated with increased morbidity, mortality, and poorer cognitive outcomes, particularly in patients with subdural hematoma 1
Meta-analysis of 16 studies confirms both agents prevent early seizures equally well, but levetiracetam's side-effect profile makes it the clear choice 4
Evidence Against Routine Prophylaxis
Universal prophylaxis for all TBI patients is not recommended. 2, 1
- Analysis of 11 clinical trials (>2,700 patients) found no significant effect of antiepileptics in preventing early or delayed post-traumatic seizures when applied universally 2
- Some studies showed worsening neurological outcomes with routine antiepileptic use 2
- Absolute risk reduction is only 0.6% in mild-to-moderate TBI, requiring treatment of 167 patients to prevent 1 seizure 5
Therefore, use a selective risk-based approach targeting only high-risk patients 2, 1
Duration: The 7-Day Rule
Do not extend prophylaxis beyond 7 days unless a clinical seizure occurs. 2, 1
- No antiepileptic drug prevents late post-traumatic seizures (occurring >7 days post-injury) 2, 4
- Meta-analysis shows neither levetiracetam (OR 0.69,95% CI 0.24-1.96) nor phenytoin (OR 0.4,95% CI 0.1-1.6) reduces late seizures compared to placebo 4
- Prolonged prophylaxis may worsen neurological outcomes 2
- Early seizures do not predict late seizures in multivariate analysis 2
Agents to Avoid
High-Dose Glucocorticoids
Never use high-dose glucocorticoids after severe TBI. 2, 1
- The CRASH trial (>10,000 patients) demonstrated higher mortality in the glucocorticoid group 2
Valproate
Avoid valproate due to increased mortality in TBI patients 1
Monitoring for Non-Convulsive Seizures
Implement continuous EEG monitoring in patients with: 1
- Depressed level of consciousness disproportionate to injury severity 1
- Hunt-Hess grade ≥3 (if subarachnoid hemorrhage present) 1
- Middle cerebral artery aneurysm location 1
- Hydrocephalus 1
Non-convulsive seizures occur in approximately 19% of stuporous or comatose patients with subarachnoid hemorrhage, typically around 18 days post-hemorrhage 1
Imaging Requirements
Head CT is mandatory to identify: 1, 3
- Acute intracranial hemorrhage
- Skull fractures
- Mass effect requiring neurosurgical intervention
CT detects 100% of acutely treatable lesions in post-traumatic seizure patients; approximately 7% require urgent surgical intervention 3
Special Populations
Pediatric Patients
Levetiracetam prophylaxis may be less effective in children, particularly: 6
- Younger children (median age 4 months had highest seizure rates) 6
- Abusive head trauma cases 6
- One study showed 17% seizure rate despite levetiracetam prophylaxis in moderate-to-severe pediatric TBI, similar to no-prophylaxis rates (20-53%) 6
Consider more aggressive monitoring in these high-risk pediatric subgroups 6
Alcohol Abuse
Alcohol abuse is the most significant risk factor for early post-traumatic seizures (OR 3.6,95% CI 2.3-5.7) 7
Strongly consider prophylaxis in patients with documented alcohol abuse, even with milder injuries 7
Common Pitfalls to Avoid
Continuing prophylaxis beyond 7 days without documented seizures—provides no benefit and may harm outcomes 2, 1
Using phenytoin routinely—inferior tolerability and outcomes compared to levetiracetam 1
Sub-therapeutic levetiracetam dosing (e.g., 250-500 mg twice daily)—many studies suggest these doses are insufficient 1
Failing to activate EMS when seizure follows loss of consciousness from head trauma—this combination mandates urgent neuroimaging 8
Allowing athletes to continue competition after knockout with seizure—immediate removal and evaluation required 8
Assuming early seizures predict late seizures—they do not in multivariate analysis 2
Neglecting EEG monitoring in patients with unexplained depressed consciousness—non-convulsive seizures are common 1
Management of Active Seizures
If clinical seizures occur despite prophylaxis:
- Benzodiazepines (lorazepam) are first-line for active seizures 1
- Continue antiepileptic therapy beyond 7 days only if seizures have occurred 2, 1
- Levetiracetam, fosphenytoin, or valproate show equal efficacy for refractory status epilepticus 1
Incidence Context
Understanding baseline risk helps target prophylaxis appropriately:
- Overall early seizure rate: 2.2% in all TBI cases 3, 7
- Hospitalized TBI with intracranial injury: 5.6% without prophylaxis 7
- Severe TBI: much higher rates (20-53% in some series) 6
- Late seizures: 2.1% overall, 11.9% in first year after severe TBI 3
This low absolute risk in unselected patients explains why universal prophylaxis is not recommended 2, 5